News

Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
Regeneron Commits to Comply with Company’s Privacy Policy and All Applicable Law; No Changes to 23andMe’s Privacy Policy or ...
Physician's Weekly2d
How Atopic Dermatitis Presents Differently Across Diverse Populations
Researchers reported key differences in atopic dermatitis presentation across racial groups and steps clinicians can take to ...
Alopecia Areata: Market Trends, Regulatory Framework, Clinical Trial Analysis, Epidemiology Analysis, Market Dynamics, Competitive Landscape 2025-2035
Includes Detailed Profiles of Industry Giants Eli Lilly & Company, Pfizer, Sun Pharmaceutical Industries, Arcutis Biotherapeutics, Bristol-Myers Squibb, AbbVie, Regeneron Pharmaceuticals, and Aclaris ...
Medscape3d
Atopic Dermatitis Linked to Higher Odds of Nonmelanoma Skin Cancer
SAN DIEGO — Patients with atopic dermatitis (AD) are at a significantly higher risk for nonmelanoma skin cancer (NMSC), ...
Medscape5d
Early Food Allergy May Increase Odds of Atopic March
Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...
Taiwan News5d
Dupixent approved in Singapore as the first-ever biologic medicine for patients with COPD
In Singapore, Dupixent is the first biologic medicine approved to treat these COPD patients. The prevalence of COPD is estimated to be around 6% of the general population [1], and it ranks as a ...
Clinical Trials Arena on MSN6d
LEO Pharma reports outcomes from Phase IIb trial of atopic dermatitis therapy
LEO Pharma has reported positive topline outcomes from the randomised Phase IIb trial of the IL-22 receptor subunit alpha 1 ...